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Abstract
Background: It has recently been shown that NDRG2 mRNA is down-regulated or undetectable
in several human cancers and cancer cell-lines. Although the function of NDRG2 is unknown, high
NDRG2 expression correlates with improved prognosis in high-grade gliomas. The aim of this study
has been to examine NDRG2 mRNA expression in colon cancer. By examining affected and normal
tissue from individuals with colorectal adenomas and carcinomas, as well as in healthy individuals,
we aim to determine whether and at which stages NDRG2 down-regulation occurs during colonic
carcinogenesis.
Methods: Using quantitative RT-PCR, we have determined the mRNA levels for NDRG2 in low-
risk (n = 15) and high-risk adenomas (n = 57), colorectal carcinomas (n = 50) and corresponding
normal tissue, as well as control tissue from healthy individuals (n = 15). NDRG2 levels were
normalised to β-actin.
Results: NDRG2 mRNA levels were lower in colorectal carcinomas compared to normal tissue
from the control group (p < 0.001). When comparing adenomas/carcinomas with adjacent normal
tissue from the same individual, NDRG2 expression levels were significantly reduced in both high-
risk adenoma (p < 0.001) and in colorectal carcinoma (p < 0.001). There was a trend for NDRG2
levels to decrease with increasing Dukes' stage (p < 0.05).
Conclusion: Our results demonstrate that expression of NDRG2 is down-regulated at a late stage
during colorectal carcinogensis. Future studies are needed to address whether NDRG2 down-
regulation is a cause or consequence of the progression of colorectal adenomas to carcinoma.
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N-myc Downstream Regulated Gene 2 (NDRG2) is a
member of a recently identified gene family which has
been implicated in human nervous system disorders and
cancer [1]. Although the four members of this family con-
tain a putative α/β-hydrolase fold, it is unclear whether or
not they have enzymatic activity [2]. NDRG1 was first
identified as a gene under negative regulation by N-myc in
early mouse development [3]. NDRG2 was identified
through sequence homology and is implicated in cell
growth, differentiation and neurodegeneration [4-7].
Recently, it has been shown that expression of NDRG2 is
transcriptionally repressed by c-Myc [8].
Several studies have suggested that NDRG2 mRNA is
down-regulated or undetectable in a number of human
cancers and cancer cell-lines [4,9-11]. Semiquantitative
RT-PCR was used to demonstrate that NDRG2 expression
levels were reduced in squamous cell carcinoma, pancre-
atic cancer and glioblastoma compared to normal tissue
[4,9,11]. NDRG2 expression levels in gliomas and menin-
giomas were significantly attenuated in high-grade com-
pared to low-grade tumors [4,10]. In meningiomas,
higher expression of NDRG2 mRNA correlated with clini-
cally less aggressive tumors [10]. Furthermore, NDRG2
was identified as a gene whose expression in high-grade
gliomas was positively correlated with survival [12].
Forced NDRG2 overexpression in a human glioblastoma
cell-line markedly inhibited cell proliferation [4]. These
findings implicate NDRG2 as a possible tumor suppressor
gene.
Prompted by the finding that NDRG2 expression corre-
lates inversely with tumor grade in various cancers, we set
out to analyse NDRG2 mRNA expression during colorec-
tal carcinogenesis in humans.
Methods
Subject population
The KAM cohort (Kolorektal cancer, Arv og Miljø) is based
primarily on the screening group of the Norwegian Color-
ectal Cancer Prevention study (the NORCCAP study, ID
number at Clinicaltrials.gov NCT00119912) in the
county of Telemark, Norway [13,14]. Additionally, a
series of colorectal cancer cases were recruited to the KAM
cohort from routine clinical work at Telemark Hospital
and Ulleval University Hospital in Oslo. A total of 20,780
men and women, age distribution 50–64 years, randomly
drawn from the population registries in Oslo (urban) and
the county of Telemark (mixed urban and rural) were
invited to have a flexible sigmoidoscopy (FS) screening
examination with or without (1:1) an additional faecal
occult blood test (FOBT). A total of 777 (4%) individuals
were excluded according to the exclusion criteria [13]. The
KAM biobank currently consists of 234 colorectal cancer,
1044 adenoma (229 high-risk, 762 low-risk and 53 hyper-
plastic polyps) and 400 control specimens. Controls were
defined as individuals with normal findings at FS. The
KAM study is approved by the Regional Committee for
Medical Research Ethics and the Norwegian Data Inspec-
torate. In the present study we have analyzed carcinomas
(n = 50), adenomas (n = 72) and controls (n = 15). Each
case was classified according to the degree of malignancy.
A sample of control tissue was collected 30 cm from the
anus of patients with adenomas, whereas two samples of
control tissue were taken from the surgical specimen from
patients with carcinomas: one sample in close proximity
(normal adjacent) and one sample as far away from the
tumor as possible (normal distant). Control samples were
collected from individuals without adenomas or carcino-
mas. The histology of the adenomas was examined by two
histopathologists independently. The degree of dysplasia
was determined as either mild/moderate (n = 52) or
severe (n = 20). The two pathologists reached the same
conclusion in all cases. Furthermore, adenomas were clas-
sified as either low-risk (n = 15) or high-risk (n = 57). A
high-risk adenoma is defined as an adenoma measuring ≥
10 mm in diameter and/or with villous components and/
or showing severe dysplasia [13]. The vast majority of
CRC samples had 75–80% tumor cells surrounded by
stroma, as evaluated by hematoxylin and eosin staining
by a pathologist. The distribution of gender and age
among controls and cases with colonic carcinoma or ade-
noma are shown in Table 1.
Table 1: Characteristics of cases and healthy persons in this study.
Controls Cases
Low-risk adenomas High-risk adenomas1 Carcinomas
n = 15 n = 15 n = 57 n = 50
Men 5 12 40 31
Women 10 3 17 19
Mean age2 (SD) 57.3 (4.9) 56.7 (4.4) 56.4 (3.8) 71.8 (10.5)
1A high-risk adenoma is defined as an adenoma measuring ≥ 10 mm in diameter and/or with villous components and/or showing severe dysplasia.
2There are significant differences in age among the four groups of healthy and affected individuals at 95% confidence level (Kruskal-Wallis test).Page 2 of 8
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The Cancer Profiling Array II (Clontech) was hybridised
with 50 ng of radioactively labelled NDRG2 probe accord-
ing to the manufacturer's instructions. The 460 bp
NDRG2 probe was generated by PCR using the primers
5'CTCACTCTGTGGAGACACCAT3' and
5'GGGTGATATCACCTCCACGCT3'. The hybridised array
was exposed to a phosphorimaging screen for 24 hours
and the intensity of each spot was quantified using Image-
Quant (Molecular Dynamics). The CPA consists of paired
cDNA samples generated from the total RNA of normal
and tumor tissue. Because the array is normalised for sev-
eral housekeeping genes, quantification of the hybridisa-
tion signal provides an estimate of relative transcript
abundance.
RT-PCR
Total RNA was purified from tissue as recommended by
the manufacturers using an e.z.n.a. Gel Extraction kit
(Omega Biotek). The tissue had been snap-frozen in liq-
uid N2 and stored at -80°C before RNA purification. RNA
purification included a DNAse treatment. The cDNA syn-
thesis was performed on approximately 200 ng RNA per
10 μl using the High Capacity cDNA Reverse Transcrip-
tion kit (Applied Biosystems, Nærum, Denmark). Quanti-
tative RT-PCR was performed on an ABI7500 sequence
detection system (Applied Biosystems) in Universal Mas-
termix (Applied Biosystems) using 220 nM probe and 700
nM primers for NDRG2. NDRG2 primers were NDRG2F:
5'CGATCCTTACCTACCACGATGTG3' and NDRG2R:
5'GCATGTCCTCGAACTGAAACAGT3' and the probe was
5'FAM-CTCAACTATAAATCTTGCTTCC-MGB-NFQ-3'.
Primers were designed using Primer Express v3.0 Software
and obtained from DNA Technology A/S. Primers were
designed within different exons and with a probe covering
the exon-exon border to prevent amplification of genomic
DNA. The probe recognises all splice forms of NDRG2. β-
actin primers and probe were obtained from Applied Bio-
systems. In a validation experiment using a control sam-
ple, a dilution series was produced and assayed for
NDRG2 and β-actin expression as described in the com-
parative Ct method [15]. When Ct values were plotted
against log dilution it was shown that the assays are quan-
titative over a range of 128-fold dilution for both NDRG2
and β-actin and that the PCR reactions have similar effi-
ciencies provided that a threshold of 0.2 is used for β-
actin, while the threshold was 0.07 for NDRG2. The
threshold is a fixed fluorescence signal above the baseline.
The Ct value of a sample is determined as the fractional
cycle number when the sample's fluorescence signal
exceeds the threshold. The threshold is thus assay-specific,
determined in the validation experiment and depends on
the background of the individual assay.
NDRG2 and β-actin mRNAs were quantified separately in
triplicates. The average standard deviations on triplicates
were 15% and 11% for NDRG2 and β-actin respectively.
The standard deviation on repeated measurements of the
same sample (internal control) in separate experiments
was 16% for NDRG2, indicating the day-to-day variation
of the assay. Negative controls (where the RNA was not
converted into cDNA) and positive controls were
included in all sets. Two independent PCR reactions of 28
samples (5%) yielded a correlation coefficient of 0.95,
indicating a high reproducibility of the assay.
Statistical analysis
GraphPad Prism 4 was used for the statistic calculations.
The data were not adjusted for sex since the incidence
ratio of colorectal cancer between genders (Male: 1128
and female: 1217 new cases in 2004) is 1:1 in Norway
[16]. P values < 0.05 were considered significant for all
statistical tests.
Results
Expression of NDRG2 mRNA in colonic adenomas and 
carcinomas
Preliminary experiments using a Cancer Profiling Array
indicated that expression of NDRG2 mRNA was reduced
in 9 out of 10 colonic tumors (Table 2). Using a two-tailed
paired t-test, the decrease in NDRG2 expression in tumors
as compared to the corresponding normal tissues was
found to be statistically significant (p < 0.01). Prompted
by this finding, we decided to analyse NDRG2 mRNA
expression in normal and neoplastic tissue in a larger
number of patients to confirm and extend our results.
Using real-time RT-PCR we have measured the levels of
NDRG2 mRNA in colonic tissue from healthy individuals
and from individuals with colorectal adenomas or carci-
noma (Table 1). It was observed that the expression of
NDRG2 mRNA in colorectal tissue is relatively low com-
pared to the expression of β-actin, which was used for nor-
malisation (Figure 1). Upon examination of the mean
values in affected tissue (low- and high-risk adenomas
and carcinoma), a trend towards a decreased NDRG2
expression with increasing tumor grade was observed (p <
0.001) (Figure 1).
Analysis of the data using a one-way ANOVA with Tukey's
post test did not show any significant difference in
NDRG2 mRNA level between the control group and either
normal or affected tissue from individuals with adenoma
(low- and high-risk). This was also the case when compar-
ing normal tissue from individuals with colorectal cancer
to the control group. However, when comparing affected
tissue from individuals with colorectal cancer to corre-
sponding tissue from a healthy control, a statistically sig-Page 3 of 8
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NDRG2 mRNA levels are down-regulated during colorectal cancer carcinogenesisFigure 1
NDRG2 mRNA levels are down-regulated during colorectal cancer carcinogenesis. mRNA expression of NDRG2 
determined by real-time RT-PCR and normalised to β-actin in healthy individuals (Control), normal and affected tissue from the 
same individual with adenomas (low- or high-risk) and colorectal carcinoma. Normal (adjacent): normal sample close to the 
carcinoma, Normal (distant): normal sample far from the carcinoma. Each dot represents mean values of triplicate determina-
tions. *** p < 0.001 compared to the control group using one-way ANOVA with a Tukey's post test. A trend of decreased 
NDRG2 expression with increasing tumor grade was observed in affected tissue (p < 0.001).
Table 2: Expression analysis of NDRG2 in colon cancer using a Cancer Profiling Array.
Sample Signal intensity Tumor/normal TNM staging Age Gender
Tumor/normal 18370/60015 0.31 II; T4N0M0 67 Female
Tumor/normal 31402/35431 0.89 I; T1N0M0 58 Female
Tumor/normal 57125/96121 0.59 IV; T4N0M0 43 Female
Tumor/normal 20382/23650 0.86 IIIB; T3N1M0 69 Female
Tumor/normal 28165/59167 0.48 IIIB; T3N1M0 35 Female
Tumor/normal 22193/12912 1.72 IIIA; T4N0M0 58 Male
Tumor/normal 18569/28122 0.66 IIIB; T4N1M0 63 Male
Tumor/normal 9863/28914 0.34 IIA; T2N0M0 73 Female
Tumor/normal 21780/34774 0.63 IIIB; T4N0M? 65 Female
Tumor/normal 22429/45939 0.49 IIIA; T3N1M0 65 Female
Expression of NDRG2 mRNA was determined by hybridisation of a Cancer Profiling Array with a NDRG2 probe. Quantification of the hybridisation 
signal for the paired samples revealed that NDRG2 expression was reduced in 9 out of 10 colon tumor samples compared to the corresponding 
normal sample. Using a two-tailed paired t-test, the decrease in NDRG2 expression in tumors compared to normal samples was found to be 
statistically significant (p < 0.01). The tumors were all diagnosed as adenocarcinoma aside from the Stage I tumor which was a tubulovillous 
adenoma. The TNM staging system describes the extent of the primary tumor (T), the absence/presence of metastasis to nearby lymph nodes (N) 
and the absence/presence of distant metastases (M).
BMC Cancer 2007, 7:192 http://www.biomedcentral.com/1471-2407/7/192nificant difference in the level of NDRG2 mRNA was
observed (p < 0.001) (Table 3).
Further analysis of the different groups of affected tissue
using a paired two-tailed t-test showed that the level of
NDRG2 in individuals with low-risk adenoma did not
show any significant difference between normal and neo-
plastic tissue. However, a comparison of normal and
high-risk adenoma from the same individual showed a
highly statistically significant reduction (p < 0.001) in
NDRG2 level. Finally, comparing the level of NDRG2
mRNA in normal tissue far (normal distant) and close
(normal adjacent) to that of the tumor in the surgical
specimens of CRC patients showed a statistically signifi-
cant difference (p < 0.001) in both cases (Table 3).
Cases of adenomas can also be classified according to the
diagnosed degree of dysplasia (mild/moderate or severe)
(Table 4). When comparing affected tissue with normal
tissue from the same individual, we found a statistically
significant difference in NDRG2 expression for individu-
als with mild/moderate dysplasia (p < 0.001) (Table 4).
Analysis of expression levels in carcinomas according to 
Dukes' staging
Colorectal cancer can be staged according to different sys-
tems. In this study all samples of colorectal carcinoma
(CRC) were classified as Dukes' stage A-C where C is the
most advanced and metastatic stage. Figure 2 presents
data showing that the level of NDRG2 mRNA decreases
with increasing Dukes' stage. By calculating linear regres-
sion on the data, the result was a statistically significant
linear trend (p < 0.05) for decreasing NDRG2 levels with
increasing tumor stage.
Expression patterns of NDRG2 between genders in 
colorectal cancer
The incidence of new cases of colorectal cancer in Norway
is in the ratio 1:1 between the two genders [16]. Dividing
all data collected in this study into groups of males and
females showed a general lower level of NDRG2 expres-
sion in females with colorectal carcinoma (both normal
and cancer tissue) (Figure 3). However, this difference was
not statistically significant using a one-way ANOVA with
Tukey's post test.
Discussion
In the present study we demonstrated that NDRG2 mRNA
expression levels were lower in colonic tumors than in
normal colon tissue from the same individual. This was
observed using two distinct subject populations, one of
which was a Norwegian cohort, the other a group of
affected individuals based on a commercially available
product. The difference in mRNA level is likely to be
reflected at the level of NDRG2 protein, since NDRG2
mRNA levels have previously been shown to correlate well
with protein levels [8].
In the Norwegian cohort, NDRG2 mRNA levels were sta-
tistically significantly reduced in colorectal carcinoma
when compared to the healthy controls. In order to exam-
ine whether the risk of carcinoma is affected by changes in
the microenvironment, expression levels of NDRG2 in the
lesion were compared to normal adjacent tissue as well as
to normal tissue distant from the tumor. NDRG2 mRNA
was statistically significantly reduced in tumor compared
to either normal tissue sample. No difference was
observed between the adjacent and distant samples, sug-
gesting that changes in NDRG2 expression in the carci-
noma are not attributable to the microenvironment.
Recent studies have demonstrated that colorectal cancer is
a heterogenous disease with distinct molecular compo-
nents. Distinct genetic or epigenetic alterations have been
identified which correlate with the location of the tumors
[17]. Although it was not investigated in this study, it
could be interesting to compare NDRG2 expression in
tumors located in either the proximal or distal colon.
There was a tendency for decreasing NDRG2 mRNA levels
with increasing tumor stage according to Dukes' staging of
the CRC samples, and this trend was found to be signifi-
Table 3: Mean values of normalised levels of NDRG2 mRNA in normal and affected colonic tissues.
mRNA level in normal 
tissue Mean (SD)
pa mRNA level in 
adenomas/carcinomas Mean (SD)
0.0407 (0.017)
0.0307 (0.011)
0.0136 (0.012)
pa pb
Control 0.034 (0.009)
Low-risk Adenoma 0.044 (0.014) NS NS NS
High-risk Adenoma 0.041 (0.012) NS NS < 0.001
Carcinoma Normal (distant) 0.027 (0.015) NS < 0.001 < 0.001c
Carcinoma Normal (adjacent) 0.034 (0.021) NS < 0.001d
NS = not significant.
a p value when expression levels were compared to the control group of healthy individuals using one-way ANOVA with a Tukey's post test.
b p value for comparison of mRNA expression levels in normal and tumor samples from the same individual using a paired two-tailed T-test.
c p value when normal (distant) and corresponding tumor sample were compared.
d p value when normal (adjacent) and corresponding tumor sample were compared.Page 5 of 8
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agreement with that observed for other cancer types where
NDRG2 expression is reduced in high-grade compared to
low-grade tumors [4,10]. This trend indicates either that
the loss of NDRG2 promotes tumor progression or that
NDRG2 is inactivated by factor(s) present at advanced
tumor stages. NDRG2 has previously been shown to be
negatively regulated by the c-Myc oncoprotein [8] and it is
possible that elevated levels of c-Myc would result in
reduced expression of NDRG2. Thus, it could be interest-
ing to elucidate whether or not an increased level of c-
Myc, which is a frequent event in colorectal cancer [18],
correlates with a decreased level of NDRG2. Measurement
of c-Myc levels was not included in these studies. How-
ever, we have investigated a subset of the CRC samples (n
= 54) from the KAM study for β-catenin expression by
immunohistochemistry. All of the tested CRC samples are
positive for cytoplasmic β-catenin and 72% are β-catenin
positive in all nuclei (data not shown). The remaining
samples contain nuclear β-catenin in occasional nuclei.
This suggests that c-Myc levels are likely to be elevated
since c-Myc is known to be positively regulated by nuclear
β-catenin [19].
In order to determine the stage at which NDRG2 expres-
sion is down-regulated in the adenoma-carcinoma
sequence we also examined normal and affected tissue
Table 4: Mean values of normalised levels of NDRG2 mRNA in adenomas1.
mRNA level in normal 
tissue Mean (SD)
pa mRNA level in 
adenomas Mean (SD)
pa pb
Mild/moderate Dysplasia 0.042 (0.012) NS 0.032 (0.014) NS < 0.001
Severe Dysplasia 0.040 (0.014) NS 0.034 (0.011) NS NS
NS = not significant.
1Cases of adenomas were divided into mild/moderate (n = 52) or severe (n = 20) according to the diagnosed degree of dysplasia.
a p value when expression levels were compared to the control group of healthy individuals using one-way ANOVA with a Tukey's post test.
b p value for comparison of mRNA expression levels in normal and tumor samples from the same individual using a paired two-tailed T-test.
NDRG2 mRNA levels decrease with increasing Dukes' stageFigure 2
NDRG2 mRNA levels decrease with increasing 
Dukes' stage. Samples with colorectal cancer (CRC) staged 
after the Dukes' staging system with 13 samples categorised 
as Dukes' A, 19 samples as Dukes' B and 18 samples as 
Dukes' C. The graph shows the normalised level of NDRG2 
mRNA in samples from the different Dukes' stages. Calculat-
ing linear regression using each column of data resulted in a 
statistically significant linear trend (p < 0.05) for a decrease in 
NDRG2 level with increasing Dukes' stage.
NDRG2mRNA levels are lower in females compared to malesFigure 3
NDRG2mRNA levels are lower in females compared 
to males. Expression levels of NDRG2 mRNA in samples 
with colorectal carcinomas (CRC) divided according to gen-
der. A general lower level of expression was observed in 
females. N (adjacent): normal sample close to the tumor, N 
(distant): normal sample far from the tumor.Page 6 of 8
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affected tissue with normal tissue from the same individ-
ual, we found a statistically significant difference for indi-
viduals with high-risk adenomas. However, when
compared to the control group of healthy individuals,
only the affected tissue from individuals with colorectal
carcinoma shows a statistically significant reduction in
NDRG2 mRNA levels. Our results suggest that down-reg-
ulation of NDRG2 expression occurs during the progres-
sion from adenoma to carcinoma.
Whether down-regulation of NDRG2 in colorectal carci-
noma is a cause or a consequence of malignant progres-
sion is at present unclear. Although the structure of
NDRG2 resembles that of a hydrolase [2], its ability to
function as an enzyme is presently unknown. It has
recently been shown that overexpression of NDRG2 in a
glioblastoma cell-line inhibits cell proliferation [4] and
that NDRG2 expression correlates positively with survival
in high-grade glioma [12]. NDRG2 levels are also reduced
in several cancer types and cell-lines [4,9-11]. Thus,
NDRG2 may have a general function in diverse tissues as
a tumor suppressor gene. Future studies will be needed to
examine whether increased NDRG2 levels in colorectal
carcinoma correlate with improved prognosis.
Conclusion
In conclusion, NDRG2 mRNA levels were decreased in
both high-risk colorectal adenoma and in colorectal carci-
noma compared to corresponding normal colonic
mucosa from the same individual. Furthermore, NDRG2
expression was reduced in colorectal carcinoma compared
to normal tissue from healthy individuals. Our results
suggest that NDRG2 down-regulation correlates with the
progression of dysplastic tissue to carcinoma. Future stud-
ies are needed to address whether NDRG2 down-regula-
tion is a cause or consequence of colorectalcarcinogenesis.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
LKV and CM conceived the idea of the study and designed
the primers and probes. EHK designed and administered
the KAM study and collected the samples. LKV, MS and
CFS extracted the RNA and carried out the cDNA synthe-
sis. SG organised the cDNA bank used in this study. GH
together with KMT were responsible for designing and
administering the NORCCAP clinical trial. IMBL was
responsible for the pathology of the cancer cases. TI con-
tributed with scientific input to the study. AL validated the
primers and probes, carried out the RT-PCR and per-
formed most of the statistical calculations. RL carried out
the Cancer Profiling Array analysis. CM and AL drafted the
manuscript. LKV helped writing the manuscript. All
authors contributed to interpretation and discussion of
the results and read and approved the final version.
Acknowledgements
This work was supported by The Norwegian Cancer Society (Grant num-
bers 51024/001 and E01-0851001), Telemark University College (Grant 
number 22069), the Norwegian Colorectal Cancer Prevention (NORC-
CAP) study, grants from the Norwegian Cancer Society and the Depart-
ment of Health and Social Affairs with the aid of EXTRA funds from the 
Norwegian Foundation for Health and Rehabilitation (2001/2/0110), East-
ern Norway Regional Health Authority, the Danish Medical Research 
Council, Novo Nordisk Foundation and the Danish Cancer Society 
(DP05117).
We thank Dr. Gunter Bock and Dr. Egil Johnson for collecting tumor tis-
sues and Dr. Steinar Aase for contributing to the pathology of the cancer 
cases.
We thank Christel A. Halberg for her excellent technical assistance.
References
1. Mitchelmore C, Buchmann-Moller S, Jensen NA: The NDRG gene
family and human nervous system disorders.  Cognitive Sciences
2007, 1:137-151 [https://www.novapublishers.com/catalog/
product_info.php?products_id=4758].
2. Shaw E, Mccue LA, Lawrence CE, Dordick JS: Identification of a
novel class in the alpha/beta hydrolase fold superfamily: The
N-myc differentiation-related proteins.  Proteins 2002,
47:163-168.
3. Shimono A, Okuda T, Kondoh H: N-myc-dependent repression
of Ndr1, a gene identified by direct subtraction of whole
mouse embryo cDNAs between wild type and N-myc
mutant.  Mech Dev 1999, 83:39-52.
4. Deng YC, Yao LB, Chau L, Ng SSM, Peng Y, Liu XP, Au WS, Wang JC,
Li FY, Ji SP, Han H, Nie XY, Li Q, Kung HF, Leung SY, Lin MCM: N-
myc downstream-regulated gene 2 (NDRG2) inhibits gliob-
lastoma cell proliferation.  Int J Cancer 2003, 106:342-347.
5. Qu XH, Zhai Y, Wei HD, Zhang CG, Xing GC, Yu YT, He FC: Char-
acterization and expression of three novel differentiation-
related genes belong to the human NDRG gene family.  Mol
Cell Biochem 2002, 229:35-44.
6. Mitchelmore C, Buchmann-Moller S, Rask L, West MJ, Troncoso JC,
Jensen NA: NDRG2: a novel Alzheimer's disease associated
protein.  Neurobiol Dis 2004, 16:48-58.
7. Choi SC, Kim KD, Kim JT, Kim JW, Yoon DY, Choe YK, Chang YS,
Paik SG, Lim JS: Expression and regulation of NDRG2 (N-myc
downstream regulated gene 2) during the differentiation of
dendritic cells.  FEBS Lett 2003, 553:413-418.
8. Zhang J, Li F, Liu X, Shen L, Liu J, Su J, Zhang W, Deng Y, Wang L, Liu
N, Han W, Zhang J, Ji S, Yang A, Han H, Yao L: The repression of
human differentiation-related gene NDRG2 expression by
Myc via Miz-1-dependent interaction with the NDRG2 core
promoter.  J Biol Chem 2006, 281:39159-39168.
9. Hummerich L, Muller R, Hess J, Kokocinski F, Hahn M, Furstenberger
G, Mauch C, Lichter P, Angel P: Identification of novel tumour-
associated genes differentially expressed in the process of
squamous cell cancer development.  Oncogene 2006,
25:111-121.
10. Lusis EA, Watson MA, Chicoine MR, Lyman M, Roerig P, Reifenberger
G, Gutmann DH, Perry A: Integrative genomic analysis identi-
fies NDRG2 as a candidate tumor suppressor gene fre-
quently inactivated in clinically aggressive meningioma.
Cancer Research 2005, 65:7121-7126.
11. Hu XL, Liu XP, Lin SX, Deng YC, Liu N, Li X, Yao LB: NDRG2
expression and mutation in human liver and pancreatic can-
cers.  World J Gastroenterol 2004, 10:3518-3521.
12. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD,
Misra A, Nigro JM, Colman H, Soroceanu L, Williams PM, Modrusan
Z, Feuerstein BG, Aldape K: Molecular subclasses of high-grade
glioma predict prognosis, delineate a pattern of disease pro-Page 7 of 8
(page number not for citation purposes)
BMC Cancer 2007, 7:192 http://www.biomedcentral.com/1471-2407/7/192Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
gression, and resemble stages in neurogenesis.  Cancer Cell
2006, 9:157-173.
13. Gondal G, Grotmol T, Hofstad B, Bretthauer M, Eide TJ, Hoff G: The
Norwegian Colorectal Cancer Prevention (NORCCAP)
screening study: baseline findings and implementations for
clinical work-up in age groups 50-64 years.  Scand J Gastroenterol
2003, 38:635-642.
14. Clinical Trials  2007 [http://clinicaltrials.gov].
15. Johnson MR, Wang K, Smith JB, Heslin MJ, Diasio RB: Quantitation
of dihydropyrimidine dehydrogenase expression by real-
time reverse transcription polymerase chain reaction.  Anal
Biochem 2000, 278:175-184.
16. Norway TCR: Cancer in Norway 2004 2006 [http://www.cancerregis
try.no]. Oslo, Infoprint
17. Sugai T, Habano W, Jiao YF, Tsukahara M, Takeda Y, Otsuka K, Naka-
mura S: Analysis of molecular alterations in left- and right-
sided colorectal carcinomas reveals distinct pathways of car-
cinogenesis: proposal for new molecular profile of colorectal
carcinomas.  J Mol Diagn 2006, 8:193-201.
18. Nesbit CE, Tersak JM, Prochownik EV: MYC oncogenes and
human neoplastic disease.  Oncogene 1999, 18:3004-3016.
19. Behrens J: The role of the Wnt signalling pathway in colorec-
tal tumorigenesis.  Biochem Soc Trans 2005, 33:672-675.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/7/192/pre
pubPage 8 of 8
(page number not for citation purposes)
